References
- Wu H, Norton V, Cui K, Zhu B, Bhattacharjee S, Lu YW, Wang B, Shan D, Wong S, Dong Y, Chan SL, Cowan D, Xu J, Bielenberg DR, Zhou C, Chen H. Diabetes and Its Cardiovascular Complications: Comprehensive Network and Systematic Analyses. Front Cardiovasc Med. 2022 Feb 17;9:841928. doi: 10.3389/fcvm.2022.841928. PMID: 35252405; PMCID: PMC8891533.
- Rabizadeh S, Nakhjavani M, Esteghamati A. Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review. Int J Endocrinol Metab. 2019 Apr 22;17(2):e84353. doi: 10.5812/ijem.84353. PMID: 31372172; PMCID: PMC6628616.
- Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. Int J Heart Fail. 2023 Mar 13;5(2):82-90. doi: 10.36628/ijhf.2022.0030. PMID: 37180562; PMCID: PMC10172076.
- Rivera FB, Cruz LLA, Magalong JV, Ruyeras JMMJ, Aparece JP, Bantayan NRB, Lara-Breitinger K, Gulati M. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024 May 7;18:100679. doi: 10.1016/j.ajpc.2024.100679. PMID: 38779187; PMCID: PMC11108827.
- Newman TV, Munshi KD, Neilson LM, Good CB, Swart ECS, Huang Y, Henderson R, Parekh N. Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study. J Manag Care Spec Pharm. 2021 Apr;27(4):435-443. doi: 10.18553/jmcp.2021.27.4.435. PMID: 33769857; PMCID: PMC10391293.
- Scheen AJ. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation. Lancet Reg Health Eur. 2023 Mar 30;29:100627. doi: 10.1016/j.lanepe.2023.100627. PMID: 37025106; PMCID: PMC10070122.
- Scheen AJ. Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation. Lancet Reg Health Eur. 2023 Mar 30;29:100627. doi: 10.1016/j.lanepe.2023.100627. PMID: 37025106; PMCID: PMC10070122.
- Simões de Carvalho F, de Brito Marques F, Lopes AE, Lima Ferreira J, Príncipe RM. Underprescription of SGLT2i and GLP-1 RA: CAREPRO-T2D (Cardiorenal Protection in Type 2 Diabetes) Cross-Sectional Study. Cureus. 2023 Jan 8;15(1):e33509. doi: 10.7759/cureus.33509. PMID: 36628395; PMCID: PMC9826698.
- Cohen LP, Isaza N, Hernandez I, Lewis GD, Ho JE, Fonarow GC, Kazi DS, Bellows BK. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2023 May 1;8(5):419-428. doi: 10.1001/jamacardio.2023.0077. PMID: 36870047; PMCID: PMC9985815.
- Yang CY, Chen YR, Ou HT, Kuo S. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review. Cardiovasc Diabetol. 2021 Jan 19;20(1):21. doi: 10.1186/s12933-020-01211-4. PMID: 33468131; PMCID: PMC7816439.
- Vesa CM, Bungau SG. Novel Molecules in Diabetes Mellitus, Dyslipidemia and Cardiovascular Disease. Int J Mol Sci. 2023 Feb 17;24(4):4029. doi: 10.3390/ijms24044029. PMID: 36835441; PMCID: PMC9961468.
- Liu J, Su X, Hao Y, Liu J; Cardio Metabolic Survey investigators. Knowledge gap and prescribing patterns of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among Chinese doctors. Sci Rep. 2024 Aug 7;14(1):18290. doi: 10.1038/s41598-024-69016-z. PMID: 39112571; PMCID: PMC11306237.